Since 2023, ITALFARMACO has been in the UK with its ITF Pharma UK subsidiary offering future-oriented medical care and tailor-made services. The UK company will be initially focused on developing new rare disease treatments, specifically targeting Duchenne Muscular Dystrophy.
As there is currently no cure for DMD, it represents an area of high unmet medical need. DMD is a fatal genetic condition that causes the progressive weakening and degeneration of muscles. It affects an estimated 2,500 people in the UK and Ireland and there is currently no cure. Thankfully, the UK offers a phenomenal array of partnerships in the management and research of DMD, alongside a positive patient environment that’s supported by patient groups, charities and specialist healthcare provider networks fighting on every front to transform the lives of people impacted by DMD.
ITF Pharma UK is committed and motivated to making a real difference in DMD and aims to harness the unique expertise of our dedicated UK team. Together with the experience and support of the ITALFARMACO group we are well placed to provide added value to the DMD community. Being in the UK allows us to be in the same space as other world leading companies, collectively striving to solve the challenges of DMD. We are passionate and determined in our quest to drive life-changing innovation, ground-breaking science, and provide progressive treatments that can support patients with DMD long term.
ITALFARMACO operates 7 state-of-the-art production facilities worldwide, which meet the highest international quality standards. Existing facilities were modernised and new production lines were expanded. ITALFARMACO constantly invests in technology to have modern, flexible facilities and a high production capacity, so patients across the world can rely on us to deliver the treatments they need.